Med-IQ cardiology
@med-iqcardiology.bsky.social
Your go-to source for cardiology education. Sharing the latest in cardiovascular medicine, guidelines and CME. @med-iq.bsky.social is a leading provider of CME-accredited content, dedicated to better healthcare for all.
Update on the efficacy and safety of Nex-Z in ATTR-CM from the phase 1 program #AHA2025 #Cardiobluesky
The phase III is on hold pending evaluation of liver-related safety events
#MedIQAHA25
The phase III is on hold pending evaluation of liver-related safety events
#MedIQAHA25
November 12, 2025 at 5:35 PM
Update on the efficacy and safety of Nex-Z in ATTR-CM from the phase 1 program #AHA2025 #Cardiobluesky
The phase III is on hold pending evaluation of liver-related safety events
#MedIQAHA25
The phase III is on hold pending evaluation of liver-related safety events
#MedIQAHA25
Finally it is here
The phase 2 Coramitug (PRX004)
Lots to think about
Placebo controlled, 2 levels 10 and 60 mg/kg
#AHA2025
#cardiobluesky
#MedIQAHA25
Paper out in t.co/cuSyqw4KBk
The phase 2 Coramitug (PRX004)
Lots to think about
Placebo controlled, 2 levels 10 and 60 mg/kg
#AHA2025
#cardiobluesky
#MedIQAHA25
Paper out in t.co/cuSyqw4KBk
November 12, 2025 at 5:35 PM
Finally it is here
The phase 2 Coramitug (PRX004)
Lots to think about
Placebo controlled, 2 levels 10 and 60 mg/kg
#AHA2025
#cardiobluesky
#MedIQAHA25
Paper out in t.co/cuSyqw4KBk
The phase 2 Coramitug (PRX004)
Lots to think about
Placebo controlled, 2 levels 10 and 60 mg/kg
#AHA2025
#cardiobluesky
#MedIQAHA25
Paper out in t.co/cuSyqw4KBk
Another look at serum TTR in ATTRibute-CM trial. Significant difference in outcomes based on dichotomizing sTTR to > vs <20
#CardioBluesky
#AHA2025
#MedIQAHA25
#CardioBluesky
#AHA2025
#MedIQAHA25
November 12, 2025 at 5:35 PM
Another look at serum TTR in ATTRibute-CM trial. Significant difference in outcomes based on dichotomizing sTTR to > vs <20
#CardioBluesky
#AHA2025
#MedIQAHA25
#CardioBluesky
#AHA2025
#MedIQAHA25
A post hoc analysis from ATTRibute-CM where acoramidis improved clinical outcomes regardless of AF status
#cardiobluesky
#AHA2025
#MedIQAHA25
#cardiobluesky
#AHA2025
#MedIQAHA25
November 12, 2025 at 5:35 PM
A post hoc analysis from ATTRibute-CM where acoramidis improved clinical outcomes regardless of AF status
#cardiobluesky
#AHA2025
#MedIQAHA25
#cardiobluesky
#AHA2025
#MedIQAHA25
LA strain but not volume was associated with outcomes in #HELIOS-B (vutrisiran vs placebo).
Vutrisiran attenuates worsening of LA strain #AHA2025
#cardiobluesky
#MedIQAHA25
Vutrisiran attenuates worsening of LA strain #AHA2025
#cardiobluesky
#MedIQAHA25
November 12, 2025 at 5:35 PM
LA strain but not volume was associated with outcomes in #HELIOS-B (vutrisiran vs placebo).
Vutrisiran attenuates worsening of LA strain #AHA2025
#cardiobluesky
#MedIQAHA25
Vutrisiran attenuates worsening of LA strain #AHA2025
#cardiobluesky
#MedIQAHA25
Effect of acoramidis vs placebo on V122I from ATTRibute-CM presented #AHA2025 and published in
@jamacardiology.com
#cardiobluesky
#MedIQAHA25
@jamacardiology.com
#cardiobluesky
#MedIQAHA25
November 12, 2025 at 5:35 PM
Effect of acoramidis vs placebo on V122I from ATTRibute-CM presented #AHA2025 and published in
@jamacardiology.com
#cardiobluesky
#MedIQAHA25
@jamacardiology.com
#cardiobluesky
#MedIQAHA25
Variant data from subgroup analysis in #ATTR-CM from the ATTRibute-CM trial and its OLE (acoramidis vs placebo)
#Cardiobluesky
#AHA2025
#MedIQAHA25
#Cardiobluesky
#AHA2025
#MedIQAHA25
November 12, 2025 at 5:35 PM
Variant data from subgroup analysis in #ATTR-CM from the ATTRibute-CM trial and its OLE (acoramidis vs placebo)
#Cardiobluesky
#AHA2025
#MedIQAHA25
#Cardiobluesky
#AHA2025
#MedIQAHA25
November 12, 2025 at 5:35 PM
November 12, 2025 at 5:35 PM
November 12, 2025 at 5:35 PM
November 12, 2025 at 5:35 PM
Proteomics in ATTR amyloidosis Authors dive into unregulated pathways and outcomes #AHA2025 #MedIQAHA25
November 12, 2025 at 5:35 PM
Proteomics in ATTR amyloidosis Authors dive into unregulated pathways and outcomes #AHA2025 #MedIQAHA25
#AHA2025
In cardiac #amyloidosis, this EKG algorithm had 97% sens and 40% spec for the diagnosis. This impacts accuracy.
#CardioBluesky
#MedIQAHA25
In cardiac #amyloidosis, this EKG algorithm had 97% sens and 40% spec for the diagnosis. This impacts accuracy.
#CardioBluesky
#MedIQAHA25
November 12, 2025 at 5:35 PM
#AHA2025
In cardiac #amyloidosis, this EKG algorithm had 97% sens and 40% spec for the diagnosis. This impacts accuracy.
#CardioBluesky
#MedIQAHA25
In cardiac #amyloidosis, this EKG algorithm had 97% sens and 40% spec for the diagnosis. This impacts accuracy.
#CardioBluesky
#MedIQAHA25
22/Thank you for joining this #CME #MedX!
To earn CME credit or view references and glossary: link.med-iq.com/oXPP2o
To earn CME credit or view references and glossary: link.med-iq.com/oXPP2o
November 10, 2025 at 4:13 PM
22/Thank you for joining this #CME #MedX!
To earn CME credit or view references and glossary: link.med-iq.com/oXPP2o
To earn CME credit or view references and glossary: link.med-iq.com/oXPP2o
21/Access additional HCM CME
Get practical, latest insights on HCM diagnosis and management: clinical.med-iq.com/activity/hcm...
Gain tools to identify HCM “red flags” and prevent missed or delayed diagnoses: clinical.med-iq.com/activity/hcm...
Get practical, latest insights on HCM diagnosis and management: clinical.med-iq.com/activity/hcm...
Gain tools to identify HCM “red flags” and prevent missed or delayed diagnoses: clinical.med-iq.com/activity/hcm...
November 10, 2025 at 4:13 PM
21/Access additional HCM CME
Get practical, latest insights on HCM diagnosis and management: clinical.med-iq.com/activity/hcm...
Gain tools to identify HCM “red flags” and prevent missed or delayed diagnoses: clinical.med-iq.com/activity/hcm...
Get practical, latest insights on HCM diagnosis and management: clinical.med-iq.com/activity/hcm...
Gain tools to identify HCM “red flags” and prevent missed or delayed diagnoses: clinical.med-iq.com/activity/hcm...
20/Patient Resource Hub.
Do your patients with oHCM need more information about living with this disease? Send them here!
From Diagnosis to Treatment: Taking Control of HCM
www.med-iq.com/taking-contr...
Do your patients with oHCM need more information about living with this disease? Send them here!
From Diagnosis to Treatment: Taking Control of HCM
www.med-iq.com/taking-contr...
November 10, 2025 at 4:13 PM
20/Patient Resource Hub.
Do your patients with oHCM need more information about living with this disease? Send them here!
From Diagnosis to Treatment: Taking Control of HCM
www.med-iq.com/taking-contr...
Do your patients with oHCM need more information about living with this disease? Send them here!
From Diagnosis to Treatment: Taking Control of HCM
www.med-iq.com/taking-contr...
19/Key takeaways:
➡️HCM is a treatable disease
➡️Most well-managed patients can expect to have a normal lifespan
➡️No restrictions are needed for aerobic exercise
➡️Seek out a COE for various options including latest medications, procedures, and trials
➡️HCM is a treatable disease
➡️Most well-managed patients can expect to have a normal lifespan
➡️No restrictions are needed for aerobic exercise
➡️Seek out a COE for various options including latest medications, procedures, and trials
November 10, 2025 at 4:13 PM
19/Key takeaways:
➡️HCM is a treatable disease
➡️Most well-managed patients can expect to have a normal lifespan
➡️No restrictions are needed for aerobic exercise
➡️Seek out a COE for various options including latest medications, procedures, and trials
➡️HCM is a treatable disease
➡️Most well-managed patients can expect to have a normal lifespan
➡️No restrictions are needed for aerobic exercise
➡️Seek out a COE for various options including latest medications, procedures, and trials
18/Recommendations for shared decision making in HCM care:
➡️Discuss genetic evaluation, activity, lifestyle, and treatments
➡️Disclose and explain risks, benefits, and expected outcomes
➡️Allow patients to voice their goals and concerns
➡️Discuss genetic evaluation, activity, lifestyle, and treatments
➡️Disclose and explain risks, benefits, and expected outcomes
➡️Allow patients to voice their goals and concerns
November 10, 2025 at 4:13 PM
18/Recommendations for shared decision making in HCM care:
➡️Discuss genetic evaluation, activity, lifestyle, and treatments
➡️Disclose and explain risks, benefits, and expected outcomes
➡️Allow patients to voice their goals and concerns
➡️Discuss genetic evaluation, activity, lifestyle, and treatments
➡️Disclose and explain risks, benefits, and expected outcomes
➡️Allow patients to voice their goals and concerns
17/Patients with HCM need to talk with their healthcare providers about their personal risk of sudden cardiac death—only 59% have done so in detail.
November 10, 2025 at 4:13 PM
17/Patients with HCM need to talk with their healthcare providers about their personal risk of sudden cardiac death—only 59% have done so in detail.